Drug Management of Prostate Cancer (Record no. 110800)

000 -LEADER
fixed length control field 04267nam a22004815i 4500
001 - CONTROL NUMBER
control field 978-1-60327-829-4
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220084512.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130607s2010 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781603278294
-- 978-1-60327-829-4
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-60327-829-4
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC254-282
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.994
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Figg, William D.
Relator term editor.
245 10 - TITLE STATEMENT
Title Drug Management of Prostate Cancer
Medium [electronic resource] /
Statement of responsibility, etc edited by William D. Figg, Cindy H. Chau, Eric J. Small.
264 #1 -
-- New York, NY :
-- Springer New York :
-- Imprint: Springer,
-- 2010.
300 ## - PHYSICAL DESCRIPTION
Extent XVII, 428p. 34 illus., 22 illus. in color.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Cell Biology of Prostate Cancer and Molecular Targets -- Cell Biology of Prostate Cancer and Molecular Targets -- Hormone Therapy -- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer -- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer -- Androgens and Prostate Cancer -- Androgen Receptor Biology in Prostate Cancer -- Androgen Receptor Antagonists -- 5-Alpha Reductase Inhibitors in Prostate Cancer -- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer -- Androgen Deprivation Therapy -- Pharmacogenetics of the Androgen Metabolic Pathway -- Chemotherapy -- Mitoxantrone -- Docetaxel -- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer -- Platinum Agents in Prostate Cancer -- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer -- Microtubule Targeting Agents -- Angiogenesis -- Principles of Antiangiogenic Therapy -- Bevacizumab in Advanced Prostate Cancer -- Thalidomide and Analogs -- Investigational Angiogenesis Inhibitors -- Pharmacogenetics of Angiogenesis -- Bone Metastasis -- Pathophysiology of Prostate Cancer Bone Metastasis -- Radiopharmaceuticals -- Bisphosphonates for Prevention and Treatment of Bone Metastases -- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer -- Calcitriol and Vitamin D Analogs -- Immunotherapy -- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches -- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer -- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX -- CTLA-4 Blockade for Prostate Cancer Treatment -- Prevention -- Prostate Cancer Chemoprevention Strategies -- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk -- Inflammation as a Target in Prostate Cancer -- Drug Development -- Challenges for the Development of New Agents in Prostate Cancer -- FDA Approval of Prostate Cancer Treatments -- Applications of Proteomics in Prostate Cancer -- Erratum to: Docetaxel -- Erratum to: Docetaxel.
520 ## - SUMMARY, ETC.
Summary, etc This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Internal medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Urology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Urology/Andrology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Internal Medicine.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chau, Cindy H.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Small, Eric J.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781603278317
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-60327-829-4
912 ## -
-- ZDB-2-SME

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue